Journal
BEHAVIOURAL PHARMACOLOGY
Volume 12, Issue 1, Pages 1-11Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00008877-200102000-00001
Keywords
BP 897; cocaine; D-amphetamine; self-administration; drug-discrimination; mouse; rhesus monkey
Funding
- NIDA NIH HHS [R01 DA11534] Funding Source: Medline
Ask authors/readers for more resources
Growing attention has been directed towards the potential involvement of the dopamine D3 receptor (D3R) in modulating effects of psychomotor stimulants. BP 897 (N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-2-naphthylrarboxamide; aka BP 4.897 and DO897) is amongst the most selective partial agonists for the D3R receptor thus far reported. BP 897 was tested for its ability to support self-administration in rhesus monkeys (0.3-30 mug/kg) and for its ability to produce cocaine- and D-amphetamine-like discriminative stimulus effects in mice (0.01-17 mg/kg i.p.). BP 897 was not self-administered above vehicle and saline levels in any of the four monkeys tested, and produced less than 30% generalization from either the cocaine or D-amphetamine stimulus. When BP 897 was administered before administrations of cocaine or D-amphetamine, percent drug-lever selections were reduced, These results suggest that BP 897 has a profile of activity suitable for consideration as a potential treatment for cocaine dependency disorders. (C) 2001 Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available